Trade BioCryst - BCRX CFD
Add to favourite- Summary
- Historical Data
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 7.36 |
Open | 7.33 |
1-Year Change | 21.76% |
Day's Range | 7.31 - 7.55 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 19, 2024 | 7.36 | 0.05 | 0.68% | 7.31 | 7.44 | 7.18 |
Dec 18, 2024 | 7.28 | -0.11 | -1.49% | 7.39 | 7.56 | 7.12 |
Dec 17, 2024 | 7.45 | 0.24 | 3.33% | 7.21 | 7.58 | 7.20 |
Dec 16, 2024 | 7.42 | 0.03 | 0.41% | 7.39 | 7.50 | 7.17 |
Dec 13, 2024 | 7.51 | 0.01 | 0.13% | 7.50 | 7.59 | 7.40 |
Dec 12, 2024 | 7.57 | -0.16 | -2.07% | 7.73 | 7.87 | 7.55 |
Dec 11, 2024 | 7.83 | -0.02 | -0.25% | 7.85 | 8.04 | 7.79 |
Dec 10, 2024 | 7.90 | 0.27 | 3.54% | 7.63 | 7.96 | 7.63 |
Dec 9, 2024 | 7.70 | 0.11 | 1.45% | 7.59 | 7.77 | 7.53 |
Dec 6, 2024 | 7.57 | -0.26 | -3.32% | 7.83 | 8.12 | 7.57 |
Dec 5, 2024 | 7.82 | 0.52 | 7.12% | 7.30 | 7.88 | 7.30 |
Dec 4, 2024 | 7.28 | 0.13 | 1.82% | 7.15 | 7.52 | 7.09 |
Dec 3, 2024 | 7.16 | -0.14 | -1.92% | 7.30 | 7.39 | 7.11 |
Dec 2, 2024 | 7.34 | -0.09 | -1.21% | 7.43 | 7.45 | 7.18 |
Nov 29, 2024 | 7.46 | 0.03 | 0.40% | 7.43 | 7.48 | 7.33 |
Nov 27, 2024 | 7.47 | -0.02 | -0.27% | 7.49 | 7.58 | 7.39 |
Nov 26, 2024 | 7.46 | 0.27 | 3.76% | 7.19 | 7.50 | 7.13 |
Nov 25, 2024 | 7.23 | -0.27 | -3.60% | 7.50 | 7.63 | 7.21 |
Nov 22, 2024 | 7.58 | 0.14 | 1.88% | 7.44 | 7.62 | 7.38 |
Nov 21, 2024 | 7.45 | 0.27 | 3.76% | 7.18 | 7.47 | 6.98 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
BioCryst Company profile
BioCryst (BCRX) is a commercial-stage biotech firm that discovers novel, oral, small-molecule medicines.
The company focuses on oral treatments for rare diseases in which significant unmet medical needs exist. BioCryst’s drug portfolio consists of ORLADEYO for prevention of hereditary angioedema. ORLADEYO has been approved in the US, EU, UK, Japan and UAE. Other drugs like RAPIACTA, RAPIVAB and PERAMIFLU are approved in select geographies.
The company is developing an oral small molecule Factor D inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases.
According to the company, its focus on rare diseases market helps it control costs effectively. BioCryst selects disease targets and product candidates in which a small molecule would offer a significant benefit over existing products or would be the first to market.
BioCryst’s US headquarters is located in Durham, North Carolina while its European headquarters is in Dublin, Ireland. Jon P Stonehouse is the chief executive officer and William P Sheridan is the chief medical officer of BioCryst.
The company was founded in 1966. It completed its initial public offering (IPO) in March 1994 and is listed on the Nasdaq stock exchange under the ticker symbol BCRX. According to the company’s price history, BCRX stock price hit an all-time high of $37.25 on 1 March 2000.
You can follow the ups and downs of the BioCryst stock price at Capital.com. Always stay on top of the latest price developments with our live BCRX stock chart.
Industry: | Bio Therapeutic Drugs |
4505 Emperor Blvd Ste 200
DURHAM
NORTH CAROLINA 27703-8457
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com